150 related articles for article (PubMed ID: 1768046)
21. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
22. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
Comoglio PM; Giordano S; Trusolino L
Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
[TBL] [Abstract][Full Text] [Related]
23. Cell culture models of multistep carcinogenesis.
Barrett JC
IARC Sci Publ; 1985; (58):181-202. PubMed ID: 3913638
[TBL] [Abstract][Full Text] [Related]
24. Transcription factors and drug resistance.
Kohno K; Uchiumi T; Niina I; Wakasugi T; Igarashi T; Momii Y; Yoshida T; Matsuo K; Miyamoto N; Izumi H
Eur J Cancer; 2005 Nov; 41(16):2577-86. PubMed ID: 16209921
[TBL] [Abstract][Full Text] [Related]
25. The role of annexins in tumour development and progression.
Mussunoor S; Murray GI
J Pathol; 2008 Oct; 216(2):131-40. PubMed ID: 18698663
[TBL] [Abstract][Full Text] [Related]
26. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
27. Prevention of carcinogenesis by protease inhibitors.
Kennedy AR
Cancer Res; 1994 Apr; 54(7 Suppl):1999s-2005s. PubMed ID: 8137328
[TBL] [Abstract][Full Text] [Related]
28. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents.
Keyomarsi K; Pardee AB
Prog Cell Cycle Res; 2003; 5():527-32. PubMed ID: 14593747
[TBL] [Abstract][Full Text] [Related]
29. New view of carcinogenesis: implications for chemotherapy and human risk assessment.
Ts'o PO; Bruce SA; Brown AR; Miller PS
Carcinog Compr Surv; 1985; 9():105-21. PubMed ID: 3902220
[No Abstract] [Full Text] [Related]
30. Functional loss of tumour suppressor genes in multistage chemical carcinogenesis.
Balmain A; Kemp CJ; Burns PA; Stoler AB; Fowlis DJ; Akhurst RJ
Princess Takamatsu Symp; 1991; 22():97-108. PubMed ID: 1844254
[TBL] [Abstract][Full Text] [Related]
31. DT-diaphorase: a target for new anticancer drugs.
Danson S; Ward TH; Butler J; Ranson M
Cancer Treat Rev; 2004 Aug; 30(5):437-49. PubMed ID: 15245776
[TBL] [Abstract][Full Text] [Related]
32. A review of the role of benzene metabolites and mechanisms in malignant transformation: summative evidence for a lack of research in nonmyelogenous cancer types.
Atkinson TJ
Int J Hyg Environ Health; 2009 Jan; 212(1):1-10. PubMed ID: 18178523
[TBL] [Abstract][Full Text] [Related]
33. Neoplastic growth: the consequence of evolutionary malignant resistance to chronic damage for survival of cells (review of a new theory of the origin of cancer).
Monceviciūte-Eringiene E
Med Hypotheses; 2005; 65(3):595-604. PubMed ID: 15919162
[TBL] [Abstract][Full Text] [Related]
34. [Regulation of the multidrug resistance (MDR)1 gene expression].
Kohno K; Kuwano M
Gan To Kagaku Ryoho; 1990 Oct; 17(10):1975-81. PubMed ID: 2221922
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
Walker J; Martin C; Callaghan R
Eur J Cancer; 2004 Mar; 40(4):594-605. PubMed ID: 14962729
[TBL] [Abstract][Full Text] [Related]
36. [Current emphasis in experimental cancer research and its relation to clinical oncology].
Seeber S
Onkologie; 1986 Oct; 9 Suppl 2():14, 17-9. PubMed ID: 3534669
[No Abstract] [Full Text] [Related]
37. Genetic pathways of two types of gastric cancer.
Tahara E
IARC Sci Publ; 2004; (157):327-49. PubMed ID: 15055305
[TBL] [Abstract][Full Text] [Related]
38. [Mechanism of multidrug resistance in human cancers].
Zhang HY
Sheng Li Ke Xue Jin Zhan; 1992 Jan; 23(1):30-5. PubMed ID: 1411422
[No Abstract] [Full Text] [Related]
39. Sixth Aspen Cancer Conference: molecular mechanisms of genetic deregulation in toxicity and carcinogenesis.
Tennant RW; Harris CC; Kaufman DG; Nesnow S; Slaga TJ; Stevenson DE; Trump BF
Mol Carcinog; 1993; 7(2):67-72. PubMed ID: 8096139
[No Abstract] [Full Text] [Related]
40. [The individualized therapy of tumors].
Mattern J; Volm M
Dtsch Med Wochenschr; 1992 Oct; 117(44):1685-9. PubMed ID: 1425274
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
